These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 15050160)
1. The colon displays an absorptive capacity of tacrolimus. Nishi K; Ishii T; Wada M; Amae S; Sano N; Nio M; Hayashi Y Transplant Proc; 2004 Mar; 36(2):364-6. PubMed ID: 15050160 [TBL] [Abstract][Full Text] [Related]
2. The expression of intestinal CYP3A4 in the piglet model. Nishi K; Ishii T; Wada M; Amae S; Sano N; Nio M; Hayashi Y Transplant Proc; 2004 Mar; 36(2):361-3. PubMed ID: 15050159 [TBL] [Abstract][Full Text] [Related]
3. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Masuda S; Uemoto S; Hashida T; Inomata Y; Tanaka K; Inui K Clin Pharmacol Ther; 2000 Jul; 68(1):98-103. PubMed ID: 10945321 [TBL] [Abstract][Full Text] [Related]
4. [Therapeutic drug monitoring of immunosuppresants]. Hashida T; Inui K Rinsho Byori; 2001 Jul; 49(7):662-4. PubMed ID: 11519126 [TBL] [Abstract][Full Text] [Related]
5. High trough levels of oral FK506 induced by loss of small intestine. Sano N; Nio M; Shimaoka S; Ishii T; Amae S; Wada M; Ohi R Pediatr Transplant; 2001 Dec; 5(6):434-8. PubMed ID: 11737769 [TBL] [Abstract][Full Text] [Related]
6. Increased tacrolimus trough levels in association with severe diarrhea, a case report. Asano T; Nishimoto K; Hayakawa M Transplant Proc; 2004 Sep; 36(7):2096-7. PubMed ID: 15518758 [TBL] [Abstract][Full Text] [Related]
7. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. Hebert MF; Fisher RM; Marsh CL; Dressler D; Bekersky I J Clin Pharmacol; 1999 Jan; 39(1):91-6. PubMed ID: 9987705 [TBL] [Abstract][Full Text] [Related]
8. Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. Masuda S; Uemoto S; Goto M; Fujimoto Y; Tanaka K; Inui K Clin Pharmacol Ther; 2004 Apr; 75(4):352-61. PubMed ID: 15060513 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and bioavailability of tacrolimus in rats with experimental renal dysfunction. Okabe H; Hashimoto Y; Inui KI J Pharm Pharmacol; 2000 Dec; 52(12):1467-72. PubMed ID: 11197074 [TBL] [Abstract][Full Text] [Related]
10. Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus. Shimomura M; Masuda S; Saito H; Sakamoto S; Uemoto S; Tanaka K; Inui K J Surg Res; 2002 Apr; 103(2):215-22. PubMed ID: 11922737 [TBL] [Abstract][Full Text] [Related]
11. Oral FK 506 blood levels are elevated in pig short bowel model: further investigations with co-administration of an intestinal CYP3A4 inhibitor. Sano N; Nio M; Ishii T; Amae S; Wada M; Nishi K; Endo N; Hayashi Y; Ohi R Transplant Proc; 2002 May; 34(3):1050-1. PubMed ID: 12034301 [No Abstract] [Full Text] [Related]
12. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Hashimoto Y; Sasa H; Shimomura M; Inui K Pharm Res; 1998 Oct; 15(10):1609-13. PubMed ID: 9794505 [TBL] [Abstract][Full Text] [Related]
13. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880 [TBL] [Abstract][Full Text] [Related]
14. Comparison of cyclosporin A and tacrolimus concentrations in whole blood between jejunal and ileal transplanted rats. Ogino Y; Kobayashi E; Fujimura A J Pharm Pharmacol; 1999 Jul; 51(7):811-5. PubMed ID: 10467956 [TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients. Nasiri-Toosi Z; Dashti-Khavidaki S; Nasiri-Toosi M; Khalili H; Jafarian A; Irajian H; Abdollahi A; Sadrai S Exp Clin Transplant; 2012 Dec; 10(6):586-91. PubMed ID: 22770208 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic study of the combination of tacrolimus and fluconazole in renal transplant patients. Lumlertgul D; Noppakun K; Rojanasthien N; Kanchanarattanakorn K; Jittikanont S; Manoyot A; Bunnachak D; Ophascharoensuk V J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S73-8. PubMed ID: 17044457 [TBL] [Abstract][Full Text] [Related]
17. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Roy JN; Barama A; Poirier C; Vinet B; Roger M Pharmacogenet Genomics; 2006 Sep; 16(9):659-65. PubMed ID: 16906020 [TBL] [Abstract][Full Text] [Related]
18. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578 [TBL] [Abstract][Full Text] [Related]
19. [Interaction between sildenafil and calcineurin inhibitors in renal transplant recipients with erectile dysfunction]. Cofán F; Gutiérrez R; Beardo P; Campistol JM; Oppenheimer F; Alcover J Nefrologia; 2002; 22(5):470-6. PubMed ID: 12497749 [TBL] [Abstract][Full Text] [Related]
20. Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. de Jonge H; Vanhove T; de Loor H; Verbeke K; Kuypers DR Br J Clin Pharmacol; 2015 Sep; 80(3):548-59. PubMed ID: 26114223 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]